COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn BHBH FPVFPV FLVFLV PVP-IPI REGNR2 LY-CoVLY RMDRMD
HCQ study #227 of 264
12/28 Pre-Exposure Prophylaxis study (treated before exposed to the virus)
Cordtz et al., Rheumatology, doi:10.1093/rheumatology/keaa897 (Peer Reviewed)
Incidence and severeness of COVID-19 hospitalisation in patients with inflammatory rheumatic disease: a nationwide cohort study from Denmark
Source   PDF   Share   Tweet
Retrospective 58,052 rheumatic disease patients in Denmark showing that RA patients have a higher risk of COVID-19 hospitalization in general. HCQ treated patients show lower risk, although this is not statistically significant with only 3 hospitalizations for HCQ treated patients.
HR 0.76 [0.23-2.52] time-dependent exposure model
HR 0.45 [0.11-1.92] time-fixed exposure model

Cordtz et al., 12/28/2020, retrospective, Denmark, Europe, peer-reviewed, 10 authors.
risk of hospitalization, 24.0% lower, RR 0.76, p = 0.67, treatment 3 of 2722 (0.1%), control 38 of 26718 (0.1%), adjusted per study, time-dependent exposure model.
risk of hospitalization, 55.0% lower, RR 0.45, p = 0.28, treatment 3 of 2722 (0.1%), control 38 of 26718 (0.1%), adjusted per study, time-fixed exposure model.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 264 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit